Lenz-Majewski syndrome (LMS) is a syndrome of intellectual disability and multiple congenital anomalies that features generalized craniotubular hyperostosis. By using whole-exome sequencing and selecting variants consistent with the predicted dominant de novo etiology of LMS, we identified causative heterozygous missense mutations in PTDSS1, which encodes phosphatidylserine synthase 1 (PSS1). PSS1 is one of two enzymes involved in the production of phosphatidylserine. Phosphatidylserine synthesis was increased in intact fibroblasts from affected individuals, and end-product inhibition of PSS1 by phosphatidylserine was markedly reduced. Therefore, these mutations cause a gain-of-function effect associated with regulatory dysfunction of PSS1. We have identified LMS as the first human disease, to our knowledge, caused by disrupted phosphatidylserine metabolism. Our results point to an unexplored link between phosphatidylserine synthesis and bone metabolism.
has been observed for any case. These characteristics and the very specific, consistent phenotype led to the hypothesis that LMS might be caused by de novo heterozygous dominant mutations in a single gene.
We collected DNA and clinical data from five unrelated LMSaffected individuals, including two who were new to this study (subjects 1 and 5) and three who were previously described (subjects 2-4) [8] [9] [10] ( Fig. 1 and Supplementary Table 1) . No pathogenic copy number variants were detected using karyotype analysis (all cases) or array comparative genomic hybridization (NimbleGen 135k) (subject 1). To identify the underlying genetic cause of LMS, we performed whole-exome sequencing in subjects 1-4 and in both parents of subjects 1 and 4 (Supplementary Table 2 ). A total of 224 genes showed at least 1 rare or previously unreported variant in 2 or more affected individuals, of which only 11 were predicted to be functionally impaired by variants fitting the predicted mode of inheritance (Supplementary Table 3) . A single gene, PTDSS1 (encoding phosphatidylserine synthase 1), contained putative mutations in all affected individuals. Three individuals (subjects 2-4) harbored an identical heterozygous missense c.1058A>G mutation encoding a p.Gln353Arg alteration. Subject 1 had a different heterozygous missense mutation, c.805C>T, encoding a p.Pro269Ser alteration. Subject 5 was a previously unreported case in whom Sanger sequencing of the PTDSS1 coding region identified a third heterozygous mutation, c.794T>C, encoding a p.Leu265Pro alteration. All variants were absent from our private exome sequencing database of phenotypically characterized samples and had not been reported in public databases 11, 12 . Each mutation was validated by Sanger sequencing (Supplementary Fig. 1 ) and was confirmed to be de novo in the four subjects for whom Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome l e t t e r s parental DNA was available. All mutations occurred at highly conserved residues ( Supplementary Fig. 2 ), affected all proteincoding transcripts of PTDSS1 and were predicted to be deleterious by all in silico tools used (Supplementary Table 4) .
Phosphatidylserine is produced in mammalian cells by two synthases-phosphatidylserine synthase 1 (PSS1), encoded by PTDSS1, and phosphatidylserine synthase 2 (PSS2), encoded by PTDSS2. PSS1 synthesizes phosphatidylserine through the exchange of l-serine with the choline moiety of phosphatidylcholine 13, 14 (Fig. 2a) . In contrast, PSS2 converts phosphatidylethanolamine into phosphatidylserine by a parallel base-exchange reaction 13, 14 . Phosphatidylserine represents 3-10% of all membrane phospholipids in mammalian tissues and cultured cells 14 . The relatively low abundance of phosphatidylserine is outweighed by its physiological importance, attributable to its unique physical and biochemical properties 15 and its specific tissue 13, 16 and subcellular distributions 13, 17 . Functions of phosphatidylserine at the cell surface, including roles in apoptosis, coagulation and the internalization of viruses, have been studied extensively, but phosphatidylserine also participates in intracellular processes by interacting with key signaling proteins such as the Ras and Rho family of GTPases and protein kinase C 13 .
The amino acid sequences of PSS1 and PSS2 are ~30% identical 18, 19 , and the residues involved in the identified alterations in PSS1 are common to PSS2. Applying alanine-scanning mutagenesis of a Chinese hamster PSS1 clone, Ohsawa et al. 20 described three groups of mutations that differentially affected PSS1 activity, protein levels and regulation (Fig. 2b) . The mutations resulting in p.Leu265Pro and p.Pro269Ser are adjacent to two mutations that increase PSS1 activity and attenuate negative feedback control of PSS1 by phosphatidylserine (Fig. 2b) . Mice lacking either Ptdss1 or Ptdss2 are viable, phenotypically normal and fertile, indicating that, in mice, PSS1 and PSS2 can compensate for each other 21, 22 . In contrast, simultaneous disruption of both genes is lethal, implying that phosphatidylserine is absolutely required for viability 21 . In exome data from the four LMS cases analyzed, there was good coverage of PTDSS2, and no previously unreported variants were identified.
The absence of an overtly aberrant phenotype in Ptdss1 knockout mice 21, 22 and the positions of the PTDSS1 missense mutations identified in our subjects with LMS suggest that these mutations cause a gain of function, possibly associated with regulatory dysfunction. This reasoning is supported by the description of at least two individuals with large 8q22.1 deletions encompassing PTDSS1 that do not have features of LMS 23 . We therefore performed enzymatic studies in skin fibroblasts from subjects 1, 4 and 5 who harbored p.Pro269Ser, p.Gln353Arg and p.Leu265Pro alterations, respectively. The in vitro serine-exchange activity of PSS1 was not notably higher in fibroblasts from the affected subjects than in control fibroblasts (Fig. 3a,b) , and PSS2 activity was similar in both groups (Fig. 3a) . We further investigated the synthesis of phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine in radiolabeling experiments with [ 3 H]serine in intact fibroblasts from subjects with LMS and control individuals. The incorporation of radiolabel into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was markedly higher in cells derived from individuals with LMS than in control cells (Fig. 3c,d ), demonstrating that these PTDSS1 mutations profoundly increase phosphatidylserine synthesis in intact fibroblasts.
We next investigated the reason why alterations in PSS1 resulted in increased phosphatidylserine synthesis in fibroblasts from individuals with LMS. We first performed reverse-transcription quantitative PCR (RT-qPCR) analysis of PTDSS1 and PTDSS2 in fibroblasts from control individuals and those with LMS and observed similar mRNA levels in the two groups (Fig. 4a,b) . Moreover, immunoblotting showed that the amount of PSS1 protein was not higher in fibroblasts from subjects with LMS than in controls (Fig. 4c) . Thus, the higher rate of synthesis of phosphatidylserine and phosphatidylethanolamine in the mutant fibroblasts (Fig. 3c,d) was not due to increased levels of PSS1, nor were any compensatory changes detected in the levels of PTDSS2 mRNA (Fig. 4b) or PSS2 activity (Fig. 3a) . To determine Note the typical craniofacial dysmorphic features (broad prominent forehead, hypertelorism, long philtrum, prognathism), wide persistent fontanel, thickness of the jaw, clavicles and ribs, and distal-limb abnormalities (brachydactyly with proximal symphalangism and progressive shortening and/or fusion of the fourth and fifth rays). Cutis laxa is most evident in subject 5. Phenotypic expression is variable: subjects 2 and 4 harbor the same PTDSS1 mutation, and subjects 2-4 were previously described, with progression of phenotypes apparent through comparison with the original report [8] [9] [10] . Informed consent was obtained for publication of the facial photographs shown.
npg l e t t e r s whether these mutations led to the impairment of end-product inhibition of PSS1, we compared phosphatidylserine synthesis in control and mutant fibroblasts in the presence and absence of exogenous phosphatidylserine 20, [24] [25] [26] . In contrast to control cells, intact fibroblasts from individuals with LMS showed incorporation of [ 3 H]serine into phosphatidylserine and phosphatidylethanolamine that was profoundly resistant to inhibition by phosphatidylserine (Fig. 4d,e) . This inhibition was specific, as addition of phosphatidylcholine instead of phosphatidylserine did not reduce the rate of phosphatidylserine synthesis (Supplementary Fig. 3 ). The in vitro enzymatic activity of phosphatidylserine synthase in lysates from control but not mutant fibroblasts was also strongly inhibited by the addition of phosphatidylserine ( Supplementary Fig. 4 and Supplementary Data Set). However, despite the marked disturbance in phosphatidylserine synthesis in fibroblasts from individuals with LMS, the amounts of cellular phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine ( Fig. 4f) remained unaltered relative to control cells.
Although one might anticipate that an increase in phosphatidylserine synthesis in the mutant cells would increase the steady-state levels of cellular phosphatidylserine, cellular phospholipid homeostasis is tightly regulated with respect to both synthesis and degradation. For example, PSS1 overexpression in HEK293 cells only slightly increases cellular phosphatidylserine levels 27 . Furthermore, overexpression of PSS1 or PSS2 in McArdle hepatoma cells does not increase cellular phosphatidylserine or phosphatidylethanolamine content 19, 28 . In addition, in the majority of PSS1-deficient 21 or PSS2-deficient 22 mouse tissues (including the brain), the levels of phosphatidylserine and phosphatidylethanolamine are not reduced, despite the 65-98% reduction in total serine-exchange activity 21 . Nevertheless, it is possible that, in individuals with LMS, the phospholipid content of specific tissues and subcellular organelles is altered (particularly with regard to phosphatidylserine and the distribution of its subclasses) so that only signaling processes important in the development and function of affected tissues are disturbed. Alternatively, the mutations in LMS Alterations found in individuals with LMS Alterations that impair PSS1 activity but not its expression Alterations that affect the production and/or stability of PSS1 Alterations that affect the regulation of PSS1, increasing its activity 1 npg l e t t e r s might disrupt an unknown function of PSS1 or lead to altered substrate specificity and/or gain of a new function. We examined the developmental consequences of the mutations identified in LMS and the resulting increases in in vivo PSS1 activity by expressing varying doses of RNA encoding the wild-type and mutant forms of human PTDSS1 in zebrafish embryos (Fig. 5) . Injection of embryos with up to 750 pg (the highest non-toxic dose) of wild-type PTDSS1 RNA at the one-cell stage did not cause any embryonic defects (Fig. 5a,d ,e,h and data not shown). In contrast, injection of embryos with RNA encoding the mutant forms of PSS1 identified in individuals with LMS caused a variety of defects in 6-40% of embryos 5 d after fertilization, even at the lowest dose tested (100 pg). Defects included craniofacial anomalies that resembled the ones in individuals with LMS ( Figs. 1 and 5d-g ). Similar defects occurred in embryos injected with RNA encoding all three missense mutations, and the frequency of the defects was dose dependent (Fig. 5h) . In each case, these findings support a gain-of-function effect of the PTDSS1 mutation. Craniofacial defects were not rescued upon coinjection with tp53 morpholino (Fig. 5h) , a well-studied apoptotic inhibitor 29 , which we confirmed by TUNEL staining inhibited apoptosis in developing embryos (data not shown). Therefore, the mechanisms underlying these defects are not likely to be caused by enhanced p53-dependent apoptotic cell death. Indeed, no gross differences in apoptosis or cell proliferation were observed in the craniofacial region of embryos overexpressing either wild-type or mutant PTDSS1 (Supplementary Figs. 5 and 6 ). In contrast, patterning of neural crest cells within the craniofacial cartilage of embryos injected with PTDSS1 RNA encoding p.Pro269Leu was abnormal (Fig. 5i-l) . The frequency of these defects was somewhat higher with RNA encoding p.Leu265Pro and p.Pro269Leu. These alterations cluster with previously studied activating mutations (Fig. 2b) , unlike the p.Gln353Arg alteration, which resides in a separate cytosolic domain. This observation might be consistent with a stronger gainof-function effect for the p.Leu265Pro and p.Pro269Leu alterations. Nevertheless, the biochemical data (Figs. 3 and 4) do not convincingly support this hypothesis, and no genotype-phenotype clinical correlations were evident (Supplementary Table 1) .
RT-qPCR showed that PTDSS1 expression was enriched in the brain and skin, as has also been observed for the corresponding genes in mouse tissues 30, 31 . Expression of PTDSS1 in bone was less pronounced than in the brain ( Supplementary Fig. 7 and Supplementary Data Set). We also analyzed data from two independent studies of array-based expression in human brain RNA derived from large numbers of samples (Supplementary Fig. 8 ). PTDSS1 expression was highest in almost all areas of the brain and throughout fetal and postnatal life, with peak expression occurring during mid-gestation. Consistent with these observations, phosphatidylserine is important for brain function and development, and levels of phosphatidylserine and phosphatidylethanolamine are particularly high in mammalian brains 16 . Indeed, dietary supplementation with phosphatidylserine is widely, albeit controversially, used for improving memory, cognitive function and exercise performance 32, 33 . It will therefore be important to understand how phosphatidylserine metabolism is disturbed in the nervous system of individuals with LMS and the specific pathogenic mechanisms that lead to their intellectual disability.
Individuals with LMS have abnormally loose skin, consistent with the cutis laxa spectrum. Skin histology showed a notable reduction in the amount of elastic tissue in one individual with LMS 3 , a finding that was confirmed by electron microscopy of a skin biopsy from subject 4 (Supplementary Fig. 9) . In electron microscopy studies, skin fibroblasts from subjects 1 and 4 showed a striking degree of cytoplasmic vacuolization (Supplementary Fig. 9 ). Some of these vacuoles appeared to contain stored material that we hypothesized could have had a lipid component. Nevertheless, we did not observe marked differences between control fibroblasts and those isolated from individuals with LMS in either neutral lipid accumulation in lipid droplets or in the levels of triacylglycerols ( Supplementary  Fig. 10 and Supplementary Data Set) .
An increasing number of metabolic disorders have been found to be associated with cutis laxa 34 . For example, autosomal recessive ATP6V0A2 mutations are associated with a phenotypic spectrum that overlaps that of LMS with respect to cutis laxa, intellectual disability, some dysmorphic features and large and late-closing anterior fontanel. 
npg l e t t e r s
Individuals with ATP6V0A2 mutations have combined N-and Olinked congenital glycosylation defects usually identified by a type 2 pattern on transferrin isoelectrofocusing 35, 36 , analysis of which was normal in subject 5. Autosomal recessive mutations in PYCR1 (encoding pyrroline-5-carboxylate reductase 1) were found to be associated with various cutis laxa syndrome phenotypes 35 that share intellectual disability and brain anomalies with LMS. Sequencing of the ATP6V0A2 and PYCR1 genes in subject 5 did not identify any variants. Because phosphatidylserine in the plasma membrane has a well-known role in the elimination of apoptotic cells by phagocytosis 13 and because both ATP6V0A2 and PYCR1 mutations influence apoptosis 35, 36 , one could hypothesize that this would also happen with PTDSS1 mutations. Nevertheless, disturbance to normal apoptosis was not evident in the zebrafish LMS model (Fig. 5h-l and Supplementary Fig. 4 ) or in the electron microscopy studies (Supplementary Fig. 9 ), although we observed a significant increase in the percentage of Annexin Vstained cells in cultured fibroblasts from individuals with LMS compared to control cells ( Supplementary Fig. 11 and Supplementary Data Set). In contrast to mutations in LMS, ATP6V0A2 and PYCR1 mutations are associated with decreased bone mineral density 35, 37 .
No direct link has been established between phosphatidylserine metabolism and known pathways involved in skeletal dysplasias with increased bone density (especially the ones classified with LMS in group 24) 38 . Nevertheless, phosphatidylserine and its calcium-binding properties have been recognized as being important in bone mineralization, physiological and pathological calcification and dentine formation 39, 40 . These processes could well be affected by changes in phosphatidylserine metabolism in LMS, as they involve the rearrangement of apoptotic cell membranes and the release of phosphatidylserineenriched vesicles 40, 41 , and are tightly regulated by the osteoblast, the chondrocyte and the odontoblast lineages, cells similar to the fibroblasts studied here. Phosphatidylserine and phosphatidylserinemimicking coating technology promote calcification and have been explored as potential clinical bone repair applications for osteointegrative biomaterials 40 . In other related skeletal dysplasias, such as Ghosal syndrome 42 and craniometaphyseal dysplasia 43 , abnormal osteoblast-osteoclast communication seems to be the basis of the pathomechanism, which might also apply in LMS. Indeed, phosphatidylserine-containing liposomes were shown to inhibit osteoclast differentiation and prevent trabecular bone loss 44 , suggesting application of phosphatidylserine as a potential pharmacological intervention in osteoporosis. We propose, therefore, that osteoclast dysfunction, usually associated with osteopetrosis, might also be implicated in the generalized bone hyperostosis and sclerosis in individuals with LMS.
In summary, we have identified de novo heterozygous PTDSS1 missense mutations as the cause of LMS, the first human genetic disease, to our knowledge, to be associated with disturbance of phosphatidylserine metabolism. Studies of fibroblasts from affected individuals demonstrate that these mutations increase the rate of phosphatidylserine synthesis and profoundly impair negative feedback regulation of PSS1 activity by phosphatidylserine. Furthermore, LMS constitutes a rare example of a disease caused by dominant heterozygous gain-offunction mutations affecting an enzyme. It will therefore be important to better understand its pathogenicity by elucidating the contextdependent mechanisms and tissue-and subcellular location-specific consequences of increased phosphatidylserine synthesis, particularly in the brain and in bone metabolism. Such research will bring valuable insights into the pathogenesis of and potential treatments for common disorders that share features with LMS, particularly intellectual disabilities and the osteosclerosis/osteoporosis spectrum of conditions. 100 500 100 500 100 500 100 500 500 
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Cases and samples. Samples were collected from five affected individuals with typical LMS from different ancestry groups (Supplementary Table 1) . Phenotypic data were collected from a detailed review of medical records, phone interviews, clinical re-evaluation and photographs. All participants provided written informed consent, and the Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee approved the study.
Exome capture and sequencing. Four affected individuals were screened by whole-exome sequencing, two as a trio including the proband and both parents. In each case, genomic DNA was enriched for exonic regions using the SureSelect All Exon 50Mb Targeted Enrichment kit (targeting 202,124 exons from 20,718 genes) from Agilent Technologies, according to the manufacturer's protocol. Captured libraries were sequenced on an Illumina HiSeq 2000 instrument using Illumina sBot clustering and HiSeq chemistries v1.0, under a paired-end 100-bp read-length protocol, with four samples per flow cell lane to achieve minimum median coverage of 60×.
Data processing. Reads were aligned to the human reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner (BWA version 0.5.9c). The GATK tool suite (GATK version v1.4-17-gd5199db) was used to call single-nucleotide variants and indels, following recommendations for singlesample calls. This analysis included preprocessing with marking of PCR duplicates using Picard (version 1.45), base quality score recalibration and local realignments. Variable quality score recalibration (VQSR) was applied using the following publicly available data sets: dbsnp_132.hg19.vcf, hapmap_3.3, 1000G_omni2.5 and Mills_Devine_2hit indel set. Variant annotation was carried out via ANNOVAR (release from 20 November 2011). Exome sequencing data are available upon request.
Data analyses and validation. In trios, variants were filtered according to a de novo mode of inheritance using an in-house script. Variants were prioritized according to frequency, predicted functional impact and occurrence in the four affected individuals, at both the sequence position and gene levels. Considering the rarity of the phenotype, we excluded variants if they were found in any sample of our in-house database containing >80 exomes from well-characterized individuals and controls that have been similarly processed. Rare and newly identified variants that were present in less than 0.5% of samples in the NCBI dbSNP Build 132 and 1000 Genomes Project databases and that affected the same gene in at least two of the four affected individuals were individually assessed. Mapping quality assessment included consideration of mapping score, coverage, bidirectional reads and genomic mappability (repeats and duplications) and visualization using the Integrative Genomics Viewer (IGV). Functional assessment included predictions from the Ensembl Variant Effect Predictor with SIFT and PolyPhen scores, as well as consideration of conservation and regulatory potential and full literature review. Prioritized variants were validated by Sanger sequencing in all affected individuals, with segregation extended to parental samples where available. Sequence coordinates for PTDSS1 were derived from NM_014754.1, and protein coordinates for PSS1 were derived from NP_055569.1.
Culture of fibroblasts.
Skin fibroblasts from subjects 1, 4 and 5 with LMS and from three controls (healthy individuals) were grown in Ham's F12 medium supplemented with 10% FBS. Tissue culture medium and FBS were from Invitrogen. All fibroblast cultures used were negative for mycoplasma contamination.
Phosphatidylserine synthase in vitro activity. Lysates were prepared by sonication (setting 4 on a probe sonicator; 2 × 10 s) of cells in 10 mM HEPES buffer (pH 7.5) containing 0.25 M sucrose. Lysates were then centrifuged at 600g for 2 min to pellet cellular debris and nuclei. Serine-exchange activity (contributed by both PSS1 and PSS2) was measured in the supernatant (25-50 µg of protein) in the presence of 10 mM calcium chloride, 4 mM hydroxylamine, 25 mM HEPES (pH 7.4) and l-[ 3 H(G)]serine (50 µCi/µmol, 0.4 mM) (PerkinElmer) 19 . Assays were performed in a 200-µl volume for 20 min at 37 °C and were terminated by the addition of chloroform/methanol (2:1 solution). The lower phase was washed three times with methanol/water
(1:1 solution), and radioactivity was measured. For specific determination of PSS1 and PSS2 activities, choline chloride (50 mM) was included in the assay mixture.
Metabolic labeling of phosphatidylserine and phosphatidylethanolamine.
Cells were grown to 70% confluence in 100-mm dishes, washed twice with Ham's F12 medium and incubated in the same medium to which we added 5 µCi/ml of l-[ 3 H(G)]serine (PerkinElmer) for 0, 2, 4 or 6 h. Lipids were extracted 46 and separated by thin-layer chromatography in the developing solvent chloroform/methanol/acetic acid/formic acid/water (70:30:12:4:2). Phospholipids were visualized by exposure to iodine vapor, and phosphatidylserine and phosphatidylethanolamine were identified by comparison to authentic phosphatidylserine and phosphatidylethanolamine (Avanti Polar Lipids). Incorporation of radioactivity into phosphatidylserine and phosphatidylethanolamine was quantified by scintillation counting.
Measurement of phospholipid mass. Lipids were extracted from cell lysates according to the method of Bligh and Dyer 46 . The lower phase from the lipid extraction was dried under a stream of nitrogen gas, and lipids were separated by thin-layer chromatography as described above. The bands corresponding to phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine were scraped from the plate, and the amount of phospholipid was determined by measuring the amount of inorganic phosphorus 47 . It is noteworthy that, in this solvent system, the phosphatidylcholine band slightly overlaps that corresponding to phosphatidylinositol.
Resistance of serine-exchange activity to inhibition by phosphatidylserine. Cells were seeded at 4 × 10 5 cells per 100-mm dish. After 3 d, cells were collected and suspended in buffer containing 10 mM HEPES (pH 7.5) and 0.25 M sucrose and were then sonicated (2 × 10 s) and centrifuged at 600g for 2 min to eliminate cell debris. After cell lysates were incubated on ice for 60 min with or without phosphatidylserine liposomes, serine-exchange activity was measured in cell lysates as described above. 46 and separated by thin-layer chromatography, and radioactivity was measured in phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine as described above.
Zebrafish experiments. Zebrafish (Danio rerio) embryos were obtained from a wild-type strain and were raised at 28.5 °C. Microinjections (~1 nl) were performed at the one-cell stage. The expression vector used was PTDSS1 (NM_014754) Human cDNA Clone (OriGene). Mutant versions of this construct were generated using the QuikChange Site-Directed Mutagenesis kit (Stratagene). The sequences for all primers are available upon request. Capped RNA was synthesized using the mMESSAGE mMACHINE kit (Ambion). Alcian blue staining of embryos was performed using standard techniques. TUNEL staining was performed using the DeadEnd Fluorometric TUNEL System (Promega), and immunostaining for phosphorylated histone H3 was performed using standard procedures. For imaging of neural crest cells, heterozygous sox10:gfp transgenic embryos were used 49 . All experiments with zebrafish were performed in compliance with local ethical and Home Office (UK) regulations, project license 70/6875.
Electron microscopy. Skin biopsies, buffy coat lymphocytes and fibroblast cultures were taken for ultrastructural examination. Samples were fixed in 2.5% glutaraldehyde buffered with 0.1 M sodium cacodylate (pH 7.2), postfixed in 1% osmium tetroxide, dehydrated in ascending grades of alcohol, processed through propylene oxide and embedded in Epon resin. Ultrathin sections were cut with a diamond knife on a Leica Ultracut UCT Ultramicrotome, placed on copper grids and stained with uranyl acetate and lead citrate. Examination was carried out with a JEOL 1400 transmission electron microscope.
Staining of neutral lipids and quantification of triacylglycerols.
Control and LMS skin fibroblasts were plated at 8 × 10 3 cells/cm 2 on glass coverslips coated with poly-d-lysine (Sigma) and cultured for 48 h in Ham's F12 medium containing 10% FBS. Cells were fixed with 4% paraformaldehyde for 15 min at room temperature and washed three times with PBS. Neutral lipids in cellular lipid droplets were stained by incubating cells with BODIPY 493/503 (Molecular Probes; 2 µg/ml in PBS) for 15 min at room temperature, and cells were then washed three times. Nuclei were stained with 100 nM 4′,6′-diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes), and cells were mounted on slides using ProlongGold (Molecular Probes). Images were acquired with a spinning-disk Olympus-IX81 confocal microscope and analyzed with Volocity software (PerkinElmer). Fluorescence was quantified using the same software. Cellular triacylglycerols were quantified using the Trig/GB kit (Roche) according to the manufacturer's instructions. Other methods. Immunoblotting was performed using polyclonal antibody to PTDSS1 (Y-19, sc-51410, Santa Cruz Biotechnology) 27 and standard methods. Cellular protein content was determined by the BCA method (Pierce) with BSA as the standard. Statistically significant differences between samples were assessed by the two-tailed Student's t test. P values of <0.05 were considered to be statistically significant.
